Takeda pens $900M biobucks pact with Carmine for non-viral gene therapy work
Takeda is set to spend nearly $1B in backloaded payments for a deal with startup Carmine Therapeutics. They will target rare diseases using gene therapies out of the biotech’s red blood cell extracellular vesicles platform, which it calls Regent.
They will initially focus on non-viral gene therapies rather than adeno-associated virus-based therapies, which can cause unwanted side effects.
